Collaboration to Produce Prototype Diagnostic Device

Collaboration to Produce Prototype Diagnostic Device to design a fully-manufacturable, prototype, point-of-care medical diagnostic device suitable for detecting kidney and cardiac biomarkers.

[ClickPress, Wed Jun 27 2007] Acrongenomics Inc., (OTCBB:AGNM) Molecular Vision Ltd and Pearson Matthews Ltd, announce today that they have joined forces to design a fully-manufacturable, prototype, point-of-care medical diagnostic device suitable for detecting kidney and cardiac biomarkers.

Pearson Matthews Ltd., the design company has a reputation built around innovation and the development of breakthrough products. This will be the first time that the Molecular Vision technology has been designed into a prototype commercial product.

The basis for the device will be the proprietary Molecular Vision technology which uses organic light emitters and photodetectors, coupled with microfluidics for the detection of biomarkers in bodily fluids. The technology was first demonstrated to the public in March 2007. The diagnosis relies on the optical characterisation of labelled biomarker molecules and can use fluorescence, absorption, chemiluminesence or any of the other usual optical detection methods.

Chris Wright, Executive Chairman of Molecular Vision, stated, “We are looking forward to working with Pearson Matthews and Acrongenomics on the development of our first commercial product. In combination, the three of us are able to provide innovative technology, product design and access to the market place.”

About Molecular Vision Ltd.

Molecular Vision is a spin-out company of Imperial Innovations Ltd. The company was founded by three Imperial College London researchers — Prof. Donal Bradley, Prof. Andrew de Mello and Dr. John de Mello — in 2002 in order to meet a clearly defined demand in the medical diagnostics, biosensors and analytical instrumentations markets: the need for miniaturized chemical and biological detectors offering high sensitivity and functionality at low cost. The company has directly addressed this market demand by inventing a novel method for optical detection based on recent advances in organic electronics and light emitting diodes combined with microfluidics technology. The company has mainly focused on applying its technology to the medical diagnostics markets. Molecular Vision recently signed a major development contract with Acrongenomics Inc. to jointly exploit and commercialize the technology.

About Acrongenomics Inc.

Acrongenomics Inc. is a publicly traded company that focuses on investing in and commercializing novel technology platforms concerning the Life Sciences sector. Acrongenomics brings novel and realistic concepts to market by transforming scientific innovations into tangible, consumer-orientated applications.

About Pearson Mathews Ltd.

Pearson Matthews is a specialist design development company with 20 years experience specifically in the healthcare sector for companies in the US and Europe.

Important Information About Forward-Looking Statements

All statements in this news release that are other than statements of historical facts are forward-looking statements which contain our current expectations about our future results. Forward-looking statements involve numerous risks and uncertainties. We have attempted to identify any forward-looking statements by using words such as "anticipates", "believes", "could", "expects", "intends", "may", "should" and other similar expressions. Although we believe that the expectations reflected in all of our forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct.

A number of factors may affect our future results and may cause those results to differ materially from those indicated in any forward-looking statements made by us or on our behalf. Such factors include our limited operating history; our need for significant capital to finance internal growth as well as strategic acquisitions; our ability to attract and retain key employees and strategic partners; our ability to achieve and maintain profitability; fluctuations in the trading price and volume of our stock; competition from other providers of similar products and services; and other unanticipated future events and conditions.

For further information concerning risks and uncertainties that may affect our future results, please review the disclosures contained in our latest filings with the SEC, including our most recent annual report on Form 10-KSB, and subsequent quarterly reports on Form 10-QSB. Other than as required by federal securities laws, we undertake no obligation to publicly update or revise any of our forward-looking statements, whether as a result of changed circumstances, new information, future events, or for any other reason occurring after the date of this news release.

Bookmark this release: Del.icio.us - Digg - Furl - Blinklist - Reddit